

1 Neonatal Paenibacilliosis: *Paenibacillus thiaminolyticus* as a Novel Cause of Neonatal Sepsis  
2 with High Risk of Sequelae in Uganda

3 Jessica E. Ericson<sup>1\*</sup>, Kathy Burgoine<sup>2,3,4,5\*</sup>, Elias Kumbakumba<sup>6\*</sup>, Moses Ochora<sup>6\*</sup>, Christine  
4 Hehnly<sup>1\*</sup>, Francis Bajunirwe<sup>6</sup>, Joel Bazira<sup>6</sup>, Claudio Fronterre<sup>7</sup>, Cornelia Hagmann<sup>7</sup>, Abhaya V.  
5 Kulkarni<sup>8</sup>, M. Senthil Kumar<sup>9</sup>, Joshua Magombe<sup>10</sup>, Edith Mbabazi-Kabachelor<sup>10</sup>, Sarah U. Morton<sup>11</sup>,  
6 Mercedeh Movassagh<sup>9</sup>, John Mugamba<sup>10</sup>, Ronald Mulondo<sup>10</sup>, Davis Natukwatsa<sup>10</sup>, Brian Nsubuga  
7 Kaaya<sup>10</sup>, Peter Olupot-Olupot<sup>4,5</sup>, Justin Onen<sup>10</sup>, Kathryn Sheldon<sup>1</sup>, Jasmine Smith<sup>1</sup>, Paddy Ssentongo<sup>1</sup>,  
8 Peter Ssenyonga<sup>10</sup>, Benjamin Warf<sup>11</sup>, Emmanuel Wegoye<sup>10</sup>, Lijun Zhang<sup>12</sup>, Julius Kiwanuka<sup>6†</sup> Δ, Joseph  
9 N. Paulson<sup>13†</sup>, James R. Broach<sup>1†</sup>, Steven J. Schiff<sup>14†</sup>

10 \*, † Contributed Equally, Δ Deceased

11 <sup>1</sup>Penn State College of Medicine, Hershey, PA, USA

12 <sup>2</sup>Department of Paediatrics and Child Health, Mbale Regional Referral Hospital, Mbale, Uganda

13 <sup>3</sup>Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

14 <sup>4</sup>Mbale Clinical Research Institute, Mbale Regional Referral Hospital, Mbale, Uganda

15 <sup>5</sup>Busitema University, Busitema, Uganda

16 <sup>6</sup>Mbarara University of Science and Technology, Mbarara, Uganda

17 <sup>7</sup>Lancaster University, Lancaster, United Kingdom

18 <sup>8</sup>Hospital for Sick Children, University of Toronto, Toronto, Canada

19 <sup>9</sup>Harvard T.H. Chan School of Public Health, Dana Farber Cancer Institute, Boston, MA, USA

20 <sup>10</sup>CURE Children's Hospital of Uganda, Mbale, Uganda

21 <sup>11</sup>Harvard Medical School, Boston, MA, USA

22 <sup>12</sup>Case Western Reserve University School of Medicine, Cleveland, OH, USA

23 <sup>13</sup>N-Power Medicine, Inc., Redwood City, CA, USA

24 <sup>14</sup>Yale University School of Medicine, New Haven, CT, USA

25  
26 **Abstract**

27 *Paenibacillus thiaminolyticus* may be an underdiagnosed cause of neonatal sepsis. We prospectively  
28 enrolled a cohort of 800 neonates presenting with a clinical diagnosis of sepsis at two Ugandan hospitals.  
29 Quantitative polymerase chain reaction specific to *P. thiaminolyticus* and to the *Paenibacillus* genus were  
30 performed on the blood and cerebrospinal fluid (CSF) of 631 neonates who had both specimen types  
31 available. Neonates with virus detected in either specimen type were considered to potentially have  
32 paenibacilliosis, (37/631, 6%). We described antenatal, perinatal, and neonatal characteristics, presenting  
33 signs, and 12-month developmental outcomes for neonates with paenibacilliosis vs. clinical sepsis. Median  
34 age at presentation was 3 (interquartile range 1, 7) days. Fever (92%), irritability (84%) and seizures  
35 (51%) were common. Eleven (30%) had an adverse outcome: 5 (14%) neonates died during the first year  
36 of life; 5 of 32 (16%) survivors developed postinfectious hydrocephalus and one (3%) additional survivor  
37 had neurodevelopmental impairment without hydrocephalus. These results highlight the need to consider  
38 local pathogen prevalence and the possibility of unusual pathogens when determining antibiotic choice  
39 for neonatal sepsis.  
40

41 Neonatal sepsis is a leading cause of early childhood death worldwide.<sup>1,2</sup> Affected infants are  
42 disproportionately from low-resource settings.<sup>2</sup> Survivors of neonatal sepsis have an increased risk of  
43 neurodevelopmental impairment<sup>3,4</sup>, hydrocephalus<sup>5</sup> and cerebral palsy.<sup>6</sup> Effective antibiotic therapy relies  
44 on identification of the causative pathogen or, in the absence of this information, empirical therapy that is  
45 broad enough to provide effective coverage of the most likely pathogens.<sup>6</sup>

46 In low-resource settings, blood and cerebrospinal fluid cultures are often unavailable or  
47 uninformative.<sup>7</sup> Cultures can be negative for a variety of reasons including low sample volume and  
48 technical limitations.<sup>8</sup> Some pathogens are unculturable or are difficult to culture using routine culture  
49 methods. Culture-independent methods to identify causative pathogens have recently become possible  
50 due to advances in molecular diagnostics. Because of their cost and technical requirements, these methods  
51 are not widely available and have only rarely been used to identify pathogens affecting neonates in low-  
52 resource settings.<sup>9,10</sup>

53 Current international guidelines recommend the combination of ampicillin and gentamicin as  
54 first-line empirical antibiotic therapy for neonates with sepsis.<sup>11</sup> However, in regions where antibiotic  
55 resistance is common, these antibiotics are not the ideal treatment for many neonatal infections.<sup>12-14</sup>  
56 Without local culture and antibiotic susceptibility testing, the risk of antibiotic resistance is unknown; in  
57 these cases, ampicillin and gentamicin may be inadequate treatment.<sup>15,16 15,16 15,16 15,16 15,16</sup>

58 In previous work, using targeted metagenomics, we found 41% of infants with postinfectious  
59 hydrocephalus, a common sequela of NS in Uganda, had a *Paenibacillus spp* infection.<sup>15,17</sup> We sought to  
60 describe the clinical syndrome of neonatal *Paenibacillus* infection among Ugandan neonates presenting  
61 with clinical signs of sepsis, to report 12-month outcomes for infants with this novel infection and to  
62 compare patient characteristic and outcomes for infants with *Paenibacillus* infection compared to infants  
63 with clinical sepsis without *Paenibacillus* detected. We hypothesized that infants with *Paenibacillus*  
64 detected would be more likely to have the composite outcome of postinfectious hydrocephalus, death or  
65 neurodevelopmental impairment than those without *Paenibacillus* detected.

## 66 **Methods**

### 67 *Study Population*

68 Ugandan neonates ( $\leq 28$  days of age) previously enrolled in a parent study were evaluated for  
69 inclusion in this subanalysis focused on *Paenibacillus* infection. The parent study enrolled 800 neonates  
70 presenting to two regional referral hospitals with clinical signs of neonatal sepsis (fever, poor feeding and  
71 lethargy; hypothermia, poor feeding, and lethargy; seizures and/or bulging fontanelle, poor feeding, and  
72 fever) were recruited. The study sites were, Mbale Regional Referral Hospital in Eastern Uganda, and  
73 Mbarara Regional Referral Hospital in Western Uganda. Neonates born at a gestational age  $< 37$  weeks or  
74  $< 2000$  grams birthweight, and those who had been diagnosed with birth asphyxia or hypoxic ischemic  
75 encephalopathy were excluded. Following informed written consent, blood and cerebrospinal fluid were  
76 collected from each neonate using aseptic technique. Infants were eligible for this subanalysis if they had  
77 sufficient blood and CSF to perform qPCR for *Paenibacillus* genus and *P. thiaminolyticus* (N=631).

### 78 *Laboratory Analysis*

79 An aliquot of each was collected into DNA/RNA preservative (DNA/RNA Shield, Zymo Corporation)  
80 and frozen at  $-80^{\circ}$  C. Additional aliquots of blood and CSF were processed in the local clinical laboratory  
81 for standard-of-care clinical tests. Once the entire cohort had been enrolled, the frozen samples were  
82 transferred to Penn State University for processing. CSF was available for 631/800 (79%) of the neonates  
83 enrolled. For these 631, we performed quantitative polymerase chain reaction (qPCR) on the blood and  
84 CSF using primers specific to both the *Paenibacillus* genus and *P. thiaminolyticus*. Neonates with  
85 detection of virus using either test were considered to have possible paenibacilliosis.

86 Demographics, birth history, clinical signs at presentation and during the hospital stay, results of  
87 laboratory tests performed as part of clinical care and antibiotics administered were abstracted from each  
88 infant's medical record. In Uganda, current clinical guidelines recommend that the umbilical cord stump  
89 receive no care (dry cord care) or be cleansed with chlorhexidine (Umbigel<sup>TM</sup>). Mothers were asked to

90 indicate how they cared for the neonate's cord stump at home including any substances applied to the  
91 cord stump prior to presentation. The presence of seizure-like movements was considered to represent  
92 seizures; no electroencephalograms were performed. Fever was defined as a temperature  $\geq 38^{\circ}$  C.

93 Infants underwent developmental assessments at 2 months, 6 months and 12 months of age using  
94 the *Bayley Scales of Infant and Toddler Development Third Edition* (BSID-III).<sup>18</sup> Population-normalized  
95 BSID-III scores range from 1 to 19 with a population mean of 10, and a standard deviation (SD) of 3.  
96 Neurodevelopmental impairment (NDI) was defined as a BSID-III score  $< -2SD$  on any of the subscales.

97 We compared the demographic characteristics, presenting clinical signs, antibiotic treatment and  
98 clinical course for patients with neonatal paenibacillosis to septic neonates without *P. thiaminolyticus*  
99 detected using Fisher's exact test for proportions and Wilcoxon rank-sum test for continuous variables.  
100 Similarly, we compared the proportion of patients with and without paenibacillosis who experienced in-  
101 patient death, infant death (death between birth and 1 year of age), postinfectious hydrocephalus (PIH),  
102 NDI, and the composite of infant death, PIH or NDI during the first 12 months of age using Fisher's exact  
103 test. Finally, for infants with paenibacillosis, we compared the proportion of patients with fever,  
104 irritability, seizure, tachypnea, respiratory distress, umbilical cord discharge, hypertonia, tachycardia,  
105 bulging fontanelle and stiff neck between the two study sites. Missingness was uncommon and no  
106 adjustment or imputation was undertaken.

107 Neonates with PIH were referred to CURE Children's Hospital of Uganda, a neurosurgical  
108 specialty hospital located in Mbale for further management. Additional specimens of CSF were collected  
109 as part of the neurosurgical evaluation. Each specimen was split into two aliquots: one that was collected  
110 into DNA/RNA preservative (DNA/RNA Shield, Zymo Corporation) and frozen at  $-80^{\circ}$  C and one that  
111 was frozen without preservative. An additional 61 infants with PIH had their CSF processed in the same  
112 manner. The fresh frozen samples were thawed and 1 mL of CSF from each patient was inoculated into a  
113 BD BACTEC lytic anaerobic medium blood culture bottle supplemented with 1 mL of defibrinated horse  
114 blood (Thermo Scientific). Culture bottles were incubated in a BD BACTECTM FX instrument and

115 monitored for bacterial growth for up to 14 days. Culture bottles that were positive for bacterial growth  
116 were subcultured on BD BBLTM Chocolate II and CDC Anaerobe 5% Sheep Blood agar plates and  
117 incubated at 37° C under anaerobic conditions (Anoxomat, Advanced Instruments). Culture bottles that  
118 remained negative after 14 days were also subcultured under anaerobic conditions though none of these  
119 resulted in bacterial growth. All subsequent culturing after initial anaerobic conditions was done  
120 aerobically. Three CSF samples were positive for growth in culture bottles. As previously described,  
121 colonies from subculture plates were used for Gram stain, organism identification by MALDI-TOF,  
122 biochemical testing, and antimicrobial susceptibility testing. Biochemical testing was performed using  
123 API 50 CH strip following manufacturers protocol. Susceptibility testing and interpretations were  
124 performed by E-test method using Clinical and Laboratory Standards Institute (CLSI) guidelines.

125         This study was approved by the Human Subjects Protection Program at The Pennsylvania State  
126 University, Pennsylvania, United States, by CURE Children’s Hospital of Uganda Institutional Review  
127 Board, the Mbarara University of Science and Technology Research Ethics Committee, and with  
128 oversight of the Ugandan National Council on Science and Technology. Informed written consent was  
129 obtained from each patient’s mother prior to enrollment. All data produced in the current study are  
130 available upon reasonable request to the authors and will be made publicly available once the parent  
131 neonatal sepsis study is published.

## 132 **Results**

### 133 *Clinical Epidemiology of Paenibacillosis*

134         Six percent (37/631) of neonates with clinical sepsis had PCR evidence of *Paenibacillus*  
135 infection. CSF PCR was positive in most cases, 35/631 (6%) patients; 1/35 (3%) of these also had a  
136 positive blood PCR. Two additional patients had a positive blood PCR but negative CSF PCR  
137 (Supplemental Table 1).

138 Postnatal age at presentation was similar for neonates with and without paenibacillosis, median  
139 age 3 (IQR 1, 7) days and 2 (1, 4) days, respectively,  $P=0.129$  (Table 1). Most neonates with  
140 paenibacillosis were born vaginally (73%) in a healthcare facility (hospital, lower level health center or  
141 private clinic) (78%). However, when compared to infants without paenibacillosis, infants with  
142 paenibacillosis detected were significantly more likely to be born at home, 6% vs. 22%, respectively,  
143  $P<0.01$  and to have received non-recommended cord stump care, 19% vs. 38%, respectively,  $P=0.01$ .

144 Neonates with paenibacillosis frequently had fever (92%) and irritability (84%) (Figure 1).  
145 Clinical seizures were present in half of neonates. A bulging fontanelle was present in 22% overall and in  
146 6/16 (38%) infants at Mbale but in only 2/21 (10%) at Mbarara,  $P=0.06$ . All other presenting signs  
147 occurred in a similar proportion of neonates at each of the two sites.

#### 148 *Laboratory studies*

149 Blood cultures grew an organism in 4/37 (14%) of neonates (Supplemental Table 2). Two grew  
150 *Staphylococcus aureus*, and one each grew a *Klebsiella species*, a *Bacillus species* and *Streptococcus*  
151 *agalactiae*. Due to testing limitations at the local microbiology laboratory, species-level identification of  
152 some organisms was not performed. One of the neonates with *S. aureus* died shortly after hospital  
153 admission. All 37 neonates had negative antigen testing for malaria. Thirty-six patients had a blood CMV  
154 PCR performed; none was positive.

155 Seventeen of the 37 paenibacillosis patients had a CSF WBC count reported. Four of the 17  
156 (24%) neonates with an available CSF WBC count had a CSF WBC count  $\geq 15$ : 20, 75, 75 and 80  $\times 10^6$   
157 cells/L. The protein concentration was  $\geq 1$  g/L in two of these four (50%) neonates (1.8, 5.4 g/L) and in  
158 an additional 6 neonates (8/37, 22%) with normal or unavailable CSF WBC counts (1, 1, 1, 2.3, 3.4, 5  
159 g/L). CSF and blood glucose concentrations were not available. No CSF culture grew bacteria in the local  
160 laboratory.

161

162 *Treatment*

163 The choice of empirical therapy was chosen by the admitting healthcare worker and therefore  
164 varied across the cohort. Most neonates with paenibacilliosis (26/37, 70%) were initially started on  
165 intravenous ampicillin plus gentamicin. Eight (21%) were treated initially with a third-generation  
166 cephalosporin (ceftriaxone or cefotaxime) along with either gentamicin (5, 13%), or an aminoglycoside,  
167 ampicillin and cloxacillin (2, 7%). Three (8%) received ampicillin, cloxacillin and gentamicin as initial  
168 therapy and 1 (3%) received ampicillin, gentamicin and ceftriaxone.

169 Antibiotic therapy was escalated to a broader antibiotic regimen for 9/37 (24%) neonates.  
170 Antibiotic escalation occurred after a median of 3 days (IQR: 3, 3). This is common practice in these  
171 hospitals, when the treating clinician does not see a good clinical response. Most commonly, ampicillin  
172 was changed to a cephalosporin (5/9, 56%). In two cases each (2/9, 22%), cloxacillin was added to  
173 ampicillin and gentamicin and in 1 case (1/9, 11%) gentamicin was changed to a cephalosporin and  
174 ampicillin was continued.

175 *Outcomes*

176 The composite poor outcome of infant death, PIH or NDI was more common in neonates with  
177 paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%),  $P=0.012$ . Among neonates with  
178 paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two  
179 sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara,  $P=0.151$  (Figure 2). Infant death following  
180 paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each  
181 site, 2/16 (13%) at Mbale and 3/21 (14%) at Mbarara,  $P=1.00$ . Three patients progressed rapidly to death  
182 prior to hospital discharge. Another infant remained critically ill during the hospital stay and was  
183 discharged to home against medical advice; this infant died shortly after discharge home. A fifth patient  
184 was treated with 5 days of ampicillin and gentamicin, was discharged home from the hospital in good  
185 condition but developed a second febrile illness and died at 2 months of age.

186           PIH was also more common among neonates with paenibacilliosis than those neonates without  
187 paenibacilliosis, 5/37 (14%) vs. 3/594 (<1%), P<0.001. Additionally, PIH occurred following  
188 paenibacilliosis more frequently at Mbale, 5/16 (31%), than at Mbarara, 0/21 (0%), P=0.010. Four of the  
189 five (80%) neonates with *Paenibacillus*-associated PIH had an elevated CSF protein concentration but all  
190 5/5 (100%) had a CSF WBC count < 100 x10<sup>6</sup> cells/L at presentation (Table 2). Two required placement  
191 of a ventricular peritoneal shunt, two were managed conservatively without surgery and one was referred  
192 for neurosurgical evaluation but was lost to follow-up. Nineteen of the 32 (59%) paenibacilliosis  
193 survivors had a developmental assessment performed at 6 months and 22/32 (69%) at 12 months; 29  
194 (91%) had a developmental assessment at 6 or 12 months of age. Three of the 4 patients with  
195 paenibacilliosis-associated PIH who remained in care had moderate/severe neurodevelopmental  
196 impairment as assessed at 6- or 12- months of age (Table 3). One additional neonate (4%) who survived  
197 without hydrocephalus had NDI at the last developmental assessment.

198           The three isolates of *P. thiaminolyticus* that were successfully cultured from infants with PIH  
199 following NS were all non-susceptible to vancomycin (Table 4). Two of the three (67%) were resistant to  
200 ampicillin. There are not interpretive criteria for the clinical significance of minimum inhibitory  
201 concentrations (MIC) for ceftriaxone but 2 of the 3 had a very low MIC and the third had an MIC of 0.25  
202 ug/mL, a concentration which is probably susceptible.<sup>19</sup>

## 203 **Discussion**

204           We describe the first cohort of neonates with sepsis due to *Paenibacillus species*; most infections  
205 were due to *P. thiaminolyticus*. Signs of meningitis such as irritability, seizures and bulging fontanelle  
206 were common at presentation. Eleven percent of neonates died during their original in-patient admission.  
207 Poor outcomes were common among survivors: PIH developed in 16% and NDI was common.

208           *P. thiaminolyticus* has rarely been reported as a cause of human disease. The first case of human  
209 infection was reported in 2008 when an 80-year-old man undergoing hemodialysis developed bacteremia



210 due to *P. thiaminolyticus*.<sup>20</sup> He received 4 weeks of vancomycin and improved. A 33-year-old Swiss  
211 woman experienced a surgical wound infection due to *P. thiaminolyticus* 7 days following an  
212 abdominoplasty procedure.<sup>21</sup> The organism was identified on culture of an aspirate from an abdominal  
213 wall fluid collection. She was treated with 2 weeks of unspecified intravenous antibiotics followed by 2  
214 weeks of amoxicillin-clavulanate as definitive therapy and completely recovered. Finally, *P.*  
215 *thiaminolyticus* was recovered on blood culture from a 25-day old neonate admitted to a hospital in the  
216 United States of America due to cardiorespiratory arrest following 1 day of poor feeding and increased  
217 sleep.<sup>22</sup> Unfortunately, the neonate succumbed to her infection 4 days later. Post-mortem examination  
218 revealed a soft brain with several areas of infarction but without clear signs of meningitis. Our finding  
219 that 33 of 631 (5%) neonates evaluated for sepsis had *P. thiaminolyticus* detected using molecular  
220 methods was unexpected and suggests that *P. thiaminolyticus* may be an underdiagnosed cause of  
221 neonatal sepsis, meningitis, and PIH in Uganda.

222         Studies seeking to identify causative organisms for neonatal sepsis may fail to identify *P.*  
223 *thiaminolyticus* for several reasons. First, this organism may have ecological niches that are not  
224 universally distributed. We failed to find any evidence of *P. thiaminolyticus* presence in the vaginal  
225 microbiome of 99 women residing in Mbale or Mbarara, Uganda at the time of delivery suggesting that  
226 neonates may become colonized with the organism through environmental, rather than maternal sources.<sup>23</sup>  
227 It has been identified in fish from Lake Michigan in the United States,<sup>24</sup> and from the soil in India.<sup>25</sup> Other  
228 species of *Paenibacillus* have been identified in the soil globally<sup>26-30</sup> and as a member of the human gut  
229 microbiome.<sup>31</sup> Some species are known to infect honeybees<sup>32</sup> and, rarely, humans.<sup>33-35</sup> Neonates cared for  
230 in industrialized or high-resource settings may have limited contact with environmental reservoirs of  
231 *Paenibacillus*. Studies evaluating neonatal pathogens in high-resource settings may fail to identify  
232 *Paenibacillus* because there are no neonatal infections in those cohorts caused by *Paenibacillus*.

233         Neonates who are born and live in environments where exposure to contaminated water and soil  
234 is common could encounter *Paenibacillus* more frequently and at higher levels. It is possible that neonatal

235 infections due to *Paenibacillus* do occur globally but are not diagnosed in either high- or low-resource  
236 settings due to the limitations of culture-based pathogen detection methods in neonates. Even common  
237 neonatal pathogens can be missed when the blood volume used to inoculate the blood culture bottles is <1  
238 mL.<sup>36,37</sup> Low sample volume will similarly have limited our ability to detect *Paenibacillus* in an infant  
239 with paenibacillosis. Blood cultures are typically incubated for 5-7 days and CSF cultures for 2-5 days.  
240 *Paenibacillus* may take 7-14 days to reach the level of detection using standard culture methods.<sup>38</sup>  
241 Cultures may be deemed negative and the specimens discarded prior to sufficient time to detect  
242 *Paenibacillus* elapsing. Studies attempting to diagnose the spectrum of pathogens causing disease in  
243 neonatal sepsis may be improved by increasing the duration of specimen incubation beyond the standard  
244 5-7 days or by using molecular methods to improve diagnostic yield.

245         In our prior work, we were able to grow *P. thiaminolyticus* from the CSF of 3 neonates with PIH  
246 by inoculating the CSF into anaerobic lytic blood culture bottles. Anaerobic blood culture bottles are not  
247 used as routine part of the evaluation of neonatal sepsis in most clinical settings but have been shown to  
248 increase the diagnostic yield of blood cultures for neonates with bacteremia.<sup>39</sup> Culture sensitivity for  
249 fastidious organisms such as *Kingella kingae* is also known to be improved when synovial fluid is  
250 incubated in a blood culture bottle.<sup>40,41</sup> The addition of an anaerobic blood culture bottle to the CSF  
251 evaluation of neonates with sepsis may improve the diagnosis of infections due to *Paenibacillus* and  
252 facultative anaerobes implicated in neonatal sepsis. Using these methods in all neonates with sepsis may  
253 not be warranted if the prevalence of infections identified using them is low. However, in research  
254 settings that attempt to describe the range of organisms infecting young infants expanding culture-based  
255 techniques to include additional types of media could potentially reduce false negatives and allow for a  
256 more complete description of the causative bacterial agents.

257         All of the neonates in our cohort with paenibacillosis were diagnosed using molecular methods.  
258 The addition of a *Paenibacillus* PCR to the evaluation of neonatal sepsis could improve the diagnosis of  
259 this emerging infection by providing a rapid, low-biomass way of identifying affected neonates. PCR and

260 other molecular methods have been shown to be useful for the diagnosis of other fastidious organisms  
261 that cause disease in neonates such as *Mycoplasma hominis*,<sup>42</sup> *Ureaplasma parvum*,<sup>43</sup> *Leptotrichia*  
262 *amnionii*,<sup>44</sup> and *Sneathia amnii*.<sup>45</sup> Epidemiological studies of neonatal serious bacterial infections that  
263 only use culture-based methods likely underestimate both the number and variety of infections caused by  
264 bacteria.

265 The diagnosis of *Paenibacillus* infection is important for the care of neonates with sepsis due to  
266 the high incidence of associated mortality and morbidity. In contrast to infections due *Streptococcus*  
267 *agalactiae* (0%<sup>46</sup>-4%<sup>47</sup>), paenibacillosis resulted in PIH in 12% of cases. Meningitis due to *E. coli* causes  
268 PIH in 18<sup>47</sup>-22%<sup>46</sup>. In our cohort, *Paenibacillus* conferred a similar risk of PIH as *E. coli* but was a more  
269 common cause of infection in our cohort (data not shown). Thus, paenibacillosis may be a leading cause  
270 of PIH in Uganda. It is unknown whether optimal treatment of neonatal paenibacillosis would reduce the  
271 incidence of PIH or NDI in the region. We assessed NDI using the BSID-III. Although the BSID-III uses  
272 age-based normative values generated from an American population, the tool has been shown to be a  
273 valid means of comparing development for young African infants to each other but not to infants from  
274 other regions of the world.<sup>48,49</sup> We found that NDI occurred following clinical neonatal sepsis in a similar  
275 proportion of infants with and without paenibacillosis.

276 The World Health Organization recommends using the combination of ampicillin and gentamicin  
277 as the empirical antibiotic regimen for neonatal sepsis due to the coverage provided against *Streptococcus*  
278 *agalactiae* (Group B streptococcus), *Escherichia coli*, and *Listeria monocytogenes*.<sup>50</sup> Regions where  
279 antibiotic resistance is common or additional organisms are typical may need to use a broader spectrum  
280 regimen empirically.<sup>51,52</sup> Our discovery that *P. thiaminolyticus* could be a common cause of culture-  
281 negative sepsis in Uganda has important implications for empiric antibiotic selection. Antibiotic  
282 susceptibility testing performed on the three isolates we successfully isolated from neonates with PIH  
283 demonstrated resistance to ampicillin and vancomycin. We additionally identified the presence of several  
284 beta-lactamase genes which could confer resistance to ampicillin.<sup>53</sup> Prior studies have found that

285 resistance to ampicillin, vancomycin, clindamycin and tetracycline is common in *Paenibacillus*  
286 species.<sup>21,54</sup> Because there are few clinical reports of *P. thiaminolyticus*, it is unknown how often  
287 resistance occurs or what antibiotic regimens would maximize the likelihood of a good outcome.

288 Inappropriate empirical antibiotic therapy has been associated with worse outcomes for neonatal  
289 sepsis.<sup>55-57</sup> These studies assume that an appropriate antibiotic is ultimately administered within 1-3 days  
290 of symptom onset.<sup>58</sup> Unfortunately, *P. thiaminolyticus* can be difficult to recover using culture and will be  
291 consistently missed in Uganda and other parts of the world where neonatal sepsis is common.<sup>59,60</sup> Thus, it  
292 is likely that many infected neonates do not receive effective antimicrobial therapy at all, thus increasing  
293 the risk of mortality and serious sequelae, including PIH. Incorporating the possibility of a difficult-to-  
294 culture organism into antibiotic guidelines and protocols has the potential to improve outcomes. Our  
295 findings suggest that the combination of a third-generation cephalosporin and gentamicin would be  
296 preferred over ampicillin and gentamicin as an empiric antibiotic regimen for neonatal sepsis in Uganda  
297 especially when meningitis is suspected. A prior study of soil *Paenibacillus species*' suggests that ~70%  
298 of isolates are susceptible to ceftriaxone, an antibiotic that has good penetration into the central nervous  
299 system.<sup>54</sup> Gentamicin is less reliable at achieving therapeutic concentrations in the central nervous system,  
300 especially if an abscess is present, but resistance appears to be quite uncommon.<sup>54,61</sup> Antibiotic  
301 susceptibility testing should be performed to guide antibiotic management in individual cases of  
302 paenibacillosis. Performing antibiotic susceptibility testing on a larger number of isolates will be  
303 important to improve our understanding of how best to care for neonates with these infections.

304 The possibility of antibiotic resistance should be considered when antibiotics are chosen to treat a  
305 neonate with paenibacillosis.<sup>62</sup> In particular, the WHO-recommended first-line antibiotic regimen for the  
306 treatment of neonatal sepsis (ampicillin plus gentamicin), is unlikely to be effective for *P.*  
307 *thiaminolyticus*. Vancomycin is commonly used for gram positive central nervous system (CNS)  
308 infections and is the drug-of-choice for CNS infections due to *Bacillus species* but should not be used  
309 empirically for treatment of *Paenibacillus* infections.<sup>63</sup> It is possible that alternate antibiotic regimens  
310 may be optimal for treatment of this novel infection. Because this organism may be an important

311 pathogen in the developing world, any antibiotic consideration would need to achieve therapeutic  
312 concentrations in the CNS, be inexpensive, easily administered, and well tolerated with few side effects.

313           Nutritional interventions may also be important adjunctive treatments for *P. thiaminolyticus*  
314 infections. This organism produces thiaminase, an uncommon bacterial enzyme which has the potential to  
315 reduce thiamine levels.<sup>24</sup> Recent studies have failed to show a mortality benefit of the combination of  
316 thiamine, vitamin C with and without hydrocortisone in mortality outcomes for adults with sepsis.<sup>64-66</sup>  
317 However, in a retrospective analysis, thiamine supplementation improved survival for adults with  
318 hospital-acquired pneumonia.<sup>67</sup> Thiamine supplementation may yet have a role for certain types of  
319 infection, in cases when sepsis is caused by a thiamine-consuming organism or when pre-existing  
320 thiamine deficiency exists.<sup>68-70</sup> Furthermore, thiamine supplementation may improve neurodevelopmental  
321 outcomes or reduce the likelihood of other sequelae, such as PIH, following neonatal sepsis even if it does  
322 not infer a survival benefit.<sup>71,72</sup> Studies evaluating the role of thiamine supplementation as adjunctive  
323 therapy for neonatal sepsis due to thiaminase-producing *P. thiaminolyticus* are needed.

324           An important area of future research will be to define the qPCR level that is clinically significant.  
325 In this report, we included all neonates who had any *Paenibacillus* result. It is possible that some infants  
326 included had infections due to other organisms, or even non-infectious reasons for presenting with clinical  
327 signs consistent with infection. Additionally, the outcomes that we present following neonatal  
328 paenibacilliosis may reflect inadequate antibiotic therapy being more common among neonates with  
329 *Paenibacillus* detected than those without. Infants with paenibacilliosis may be more likely to receive  
330 ineffective antibiotic therapy than infants without paenibacilliosis. This could explain some of the  
331 increased frequency of poor outcomes in infants with *Paenibacillus* detected. Since the causative  
332 pathogen was unknown in the majority of non-paenibacilliosis cases, we were not able to assess  
333 antibiotic-microbe concordance in order to assess for this possibility.

334

335 **Conclusion**

336 *Paenibacillus species* was identified in 6% of neonates with signs of sepsis who presented to two  
337 Ugandan referral hospitals; most of these were *P. thiaminolyticus*. Improved diagnostics for neonatal  
338 sepsis are urgently needed in the region. Optimal antibiotic treatment for this infection is unknown but  
339 ampicillin and vancomycin will be ineffective in many cases. The role of thiamine supplementation as  
340 adjunctive therapy is unknown but rational to consider.

341

342 **Acknowledgements**

343 This study and the parent neonatal sepsis study were funded by the National Institutes of Health under  
344 1DP1HD086071(S.J.S) and 1R01AI145057 (S.J.S). J.E.E. was supported by National Center for  
345 Advancing Translational Sciences grant #KL2 TR002015.

346

347

348

349

350

351

352

353

354

355

356 Table 1. Demographics of neonates with clinical sepsis due with and without *Paenibacillus*  
 357 *thiaminolyticus* detected by qPCR.

	Paenibacillus PCR Positive N=37 (6%)	Paenibacillus PCR Negative N=594 (94%)	P
Median age at sepsis presentation, days (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	3 (1, 7)	2 (1, 4)	0.129
<3 days	22 (61)	433 (73)	
3-7 days	6 (17)	55 (9)	
8-14 days	7 (19)	46 (8)	
>14 days	1 (3)	59 (10)	
Median gestational age at birth, weeks (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	39 (38, 40)	40 (39, 41)	0.266
Median birth weight, g (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	3200 (3000, 3500)	3200 (2900, 3500)	0.505
Sex			
Female	20 (54)	335 (56)	0.865
Male	17 (46)	259 (44)	
Maternal HIV status			0.209
Positive	4 (11)	29 (5)	
Negative	31 (84)	539 (91)	
Unknown	2 (5)	27 (5)	
Median maternal age, years (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	26 (23, 30)	24 (21, 29)	0.443

Median maternal parity (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	2 (1, 4)	2 (1, 4)	0.402
Maternal fever during pregnancy	19 (51)	333 (51)	0.608
Maternal fever during labor	8 (22)	164 (28)	0.487
Delivery location			
Healthcare	29 (78)	555 (94)	0.003*
Hospital	21 (57)	422 (71)	
Health center	7 (19)	113 (19)	
Clinic	1 (3)	20 (3)	
Home	8 (22)	36 (6)	
Delivery mode			0.166
Vaginal	27 (73)	361 (61)	
C-section	10 (27)	230 (39)	
Rupture of membranes >18 hours	8 (24)	101 (19)	0.495
Umbilical cord care			
None	23 (62)	475 (81)	0.011†
Any substance	14 (38)	113 (19)	
Saliva	6 (16)	41 (7)	
Cosmetic	6 (16)	35 (6)	
Plant material	2 (5)	28 (5)	
Other	0 (0)	9 (10)	
Feeding method			0.123
Exclusively breast fed	34 (92)	561 (94)	
Breast milk and water	1 (3)	1 (<1)	
Breast milk and replacement feeding	1 (3)	20 (3)	
Replacement feeding	1 (3)	4 (1)	



	Unknown	0 (0)	8 (1)	
Location				0.085
	Mbarara	21 (57)	244 (41)	
	Mbale	16 (43)	350 (59)	

358 \*Fisher's exact test comparing the proportion of patients with and without *Paenibacillus* detected who  
359 were born at home vs. in a healthcare facility (clinic, health centre or hospital); †Fisher's exact test  
360 comparing the proportion of patients with and without *Paenibacillus* detected who had any vs. no  
361 substances applied to the umbilical cord stump.

362 Table 2. Description of neonates who developed postinfectious hydrocephalus following neonatal sepsis with *P. thiaminolyticus* detected by qPCR

	1	2	3	4	5
Age at presentation	8-14 days	< 3 days	8-14 days	3-7 days	3-7 days
Sex	Female	Male	Male	Male	Male
Birth location	Home	Home	Home	Home	Home
Cord care	Cosmetic powder	Cosmetic powder	Vaseline	None	None
Presenting signs	Fever, poor feeding, irritability, bulging fontanelle, lethargy, seizure, umbilical discharge	Fever, poor feeding, irritability, bulging fontanelle, lethargy, seizure, hypertonia	Fever, poor feeding, irritability, bulging fontanelle, lethargy, respiratory distress, hypotonia	Fever, poor feeding, irritability, lethargy, vomiting, seizure, hypotonia	Fever, poor feeding, irritability, lethargy, seizure, stiff neck, hypertonia
CSF cell count, 10 <sup>6</sup> cells/L	≤5	75	80	≤5	≤5
CSF protein, g/L	3.4	1.8	0.5	1	2.3

Blood culture result	Negative	Negative	Negative	Negative	Negative
Admission heart rate, beats/minute	125	148	138	136	131
Admission respiratory rate, breaths/minute	36	51	67	59	47
Initial antibiotic treatment	3 days ampicillin/gentamicin,	2 days ampicillin/gentamicin	2 days ampicillin/gentamicin	7 days ceftriaxone/gentamicin	9 days ampicillin/gentamicin
Additional antibiotic treatment	11 days ceftriaxone/gentamicin	7 days ceftriaxone/gentamicin, 14 days ceftriaxone/amikacin 14 days enteral amoxicillin/ciprofloxacin/metronidazole	4 days cefotaxime/gentamicin, 14 days ceftriaxone/amikacin		

Hydrocephalus treatment	None	Shunted	Shunted	None	None
6-month outcome	Moderate cognitive and motor impairment	Not seen	Moderate cognitive and motor impairment	Normal	Not seen
12-month outcome	Not seen	Moderate cognitive and motor impairment	Not seen	Normal	Not seen

Table 3. Developmental outcomes for survivors of neonatal sepsis with *P. thiaminolyticus* detected by qPCR


	<b>6 months</b> N=19 (%)	<b>12 months</b> N=22 (%)	<b>Last follow up</b> N=29 (%)
Scaled cognitive score, mean $\pm$ SD	11 $\pm$ 5	13 $\pm$ 3	13 $\pm$ 5
Moderate/severe impairment	2 (11)	1 (5)	3 (10)
Scaled fine motor score, mean $\pm$ SD	12 $\pm$ 5	12 $\pm$ 3	12 $\pm$ 5
Moderate/severe impairment	2 (11)	1 (5)	2 (7)
Scaled gross motor score, mean $\pm$ SD	11 $\pm$ 4	10 $\pm$ 4	9 $\pm$ 4
Moderate/severe impairment	2 (11)	2 (9)	4 (14)
Scaled receptive communication score, mean $\pm$ SD	10 $\pm$ 4	10 $\pm$ 3	10 $\pm$ 4
Moderate/severe impairment	2 (11)	1 (5)	2 (7)
Scaled expressive communication score, mean $\pm$ SD	9 $\pm$ 4	10 $\pm$ 2	10 $\pm$ 3
Moderate/severe impairment	2 (11)	0 (0)	3 (10)

Table 4. E-test Antibiotic susceptibility testing results for *P. thiaminolyticus* isolates obtained from 3 infants with post-infectious hydrocephalus as a sequela of neonatal sepsis.

	Mbale		Mbale2		Mbale3	
	MIC ( $\mu\text{g/mL}$ )	Interpretation	MIC ( $\mu\text{g/mL}$ )	Interpretation	MIC ( $\mu\text{g/mL}$ )	Interpretation
Ampicillin	0.12	S	1	R	0.5	R
Ceftriaxone	0.03	**	0.25	**	0.06	**
Ciprofloxacin	0.12	S	0.12	S	0.12	S
Clindamycin	1	I	1	I	4	R
Gentamicin	2	S	2	S	2	S
Penicillin	0.12	S	0.5	R	0.25	R
Meropenem	0.25	S	0.5	S	0.5	S
Tetracycline	0.5	S	2	S	2	S
Vancomycin	8	Nonsusceptible	8	Nonsusceptible	8	Nonsusceptible


MIC: minimum inhibitory concentration; S: susceptible; R: resistant; I: intermediate

Figure 1. Presenting signs and outcomes for neonates with *Paenibacillus thiaminolyticus* detected by qPCR during clinical sepsis.



Number of neonates presenting to each site with each sign of infection. Numbers at the end of each bar indicate the proportion of neonates at each site who had the corresponding sign of infection. Neonates with the composite poor outcome of death, postinfectious hydrocephalus or moderate/severe neurodevelopmental impairment are indicated in red.

Figure 2. Outcomes for neonates with clinical sepsis with *Paenibacillus* negative (PN) and *Paenibacillus* positive (PP) qPCR results for *Paenibacillus thiaminolyticus* detection in the CSF at both sites and at Mbarara and Mbale.





Supplemental Table 1. *Paenibacillus* genus and *Paenibacillus thiaminolyticus* qPCR results from blood and cerebrospinal fluid.

Subject	Cerebrospinal Fluid		Blood	
	<i>Paenibacillus</i> genus	<i>Paenibacillus thiaminolyticus</i>	<i>Paenibacillus</i> genus	<i>Paenibacillus thiaminolyticus</i>
1	51,846	909	ND	ND
2	419,144	926,763	ND	ND
3	540,471	905,393	ND	ND
4	335	509	ND	ND
5	ND	255,011	ND	ND
6	55	1749	ND	ND
7	62	ND	ND	ND
8	118	ND	ND	ND
9	147	ND	ND	ND
10	151	ND	ND	ND
11	152	1585	ND	ND
12	178	1217	ND	ND
13	204	ND	ND	ND
14	208	2048	ND	ND
15	212	2225	ND	ND
16	240	ND	ND	ND
17	245	1606	ND	ND
18	280	ND	ND	ND
19	324	ND	ND	ND
20	363	3704	ND	ND
21	462	4537	ND	ND
22	742	1930	ND	ND
23	955	1171	ND	ND
24	1077	2848	ND	ND
25	1094	6549	ND	ND
26	1456	ND	ND	ND
27	22,561	1427	ND	ND
28	27,897	1437	ND	ND
29	30,023	1011	ND	ND
30	32,109	43,556	ND	ND
31	68,263	2505	ND	ND
32	140,435	12,387	5846	12,541
33	173,836	ND	ND	ND
34	300,260	ND	ND	ND
35	ND	827	ND	ND
36	ND	ND	ND	699
37	ND	ND	ND	214

ND: not detected

Supplemental Table 2. Results of blood polymerase chain reaction tests for cytomegalovirus and blood cultures for neonates with and without *Paenibacillus* detected.

	Paenibacillus PCR Positive N=37 (%)	Paenibacillus PCR Negative N=594 (%)
CMV		
Positive	0 (0)	15 (3)
Negative	36 (97)	564 (95)
Unknown	1 (3)	15 (3)
Blood culture	5 (15)	82 (14)
Not done	3 (8)	14 (2)
No growth	29 (78)	498 (84)
<i>Staphylococcus aureus</i>	2 (5)	48 (8)
<i>Klebsiella species</i>	1 (3)	8 (1)
<i>Bacillus species</i>	1 (3)	4 (1)
<i>Streptococcus agalactiae</i>	1 (3)	(0)
<i>Micrococcus species</i>		9 (2)
<i>Corynebacterium species</i>		4 (1)
<i>Escherichia coli</i>		3 (1)
Unspecified coliform		3 (1)
Coagulase-negative staphylococcus		2 (<1)
<i>Haemophilus species</i>		1 (<1)

## References

1. Taylor AW, Blau DM, Bassat Q, et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. *Lancet Glob Health* 2020;8(7):e909-e919. (In eng). DOI: 10.1016/S2214-109X(20)30205-9.
2. Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. *Arch Dis Child* 2021 (In eng). DOI: 10.1136/archdischild-2020-320217.
3. Shim SY, Cho SJ, Park EA. Neurodevelopmental Outcomes at 18-24 Months of Corrected Age in Very Low Birth Weight Infants with Late-onset Sepsis. *J Korean Med Sci* 2021;36(35):e205. (In eng). DOI: 10.3346/jkms.2021.36.e205.
4. Shadbolt R, We MLS, Kohan R, et al. Neonatal Staphylococcus Aureus Sepsis: a 20-year Western Australian experience. *J Perinatol* 2022 (In eng). DOI: 10.1038/s41372-022-01440-3.
5. Warf BC, Dagi AR, Kaaya BN, Schiff SJ. Five-year survival and outcome of treatment for postinfectious hydrocephalus in Ugandan infants. *J Neurosurg Pediatr* 2011;8(5):502-8. (In eng). DOI: 10.3171/2011.8.PEDS11221.
6. Al-Matary A, Al Sulaiman M, Al-Otaiby S, Qaraqei M, Al-Matary M. Association between the timing of antibiotics administration and outcome of neonatal sepsis. *J Infect Public Health* 2022;15(6):643-647. (In eng). DOI: 10.1016/j.jiph.2022.05.004.
7. Saha SK, Schrag SJ, El Arifeen S, et al. Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study. *Lancet* 2018;392(10142):145-159. (In eng). DOI: 10.1016/S0140-6736(18)31127-9.
8. Connell TG, Rele M, Cowley D, BATTERY JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. *Pediatrics* 2007;119(5):891-6. (In eng). DOI: 10.1542/peds.2006-0440.
9. Obiero CW, Gumbi W, Mwakio S, et al. Detection of pathogens associated with early-onset neonatal sepsis in cord blood at birth using quantitative PCR. *Wellcome Open Res* 2022;7:3. (In eng). DOI: 10.12688/wellcomeopenres.17386.2.
10. Velaphi SC, Westercamp M, Moleleki M, et al. Surveillance for incidence and etiology of early-onset neonatal sepsis in Soweto, South Africa. *PLoS One* 2019;14(4):e0214077. (In eng). DOI: 10.1371/journal.pone.0214077.
11. Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children. *Paediatr Int Child Health* 2018;38(sup1):S3-S15. (In eng). DOI: 10.1080/20469047.2017.1408738.
12. Labi AK, Enweronu-Laryea CC, Nartey ET, et al. Bloodstream Infections at Two Neonatal Intensive Care Units in Ghana: Multidrug Resistant Enterobacterales Undermine the Usefulness of Standard Antibiotic Regimes. *Pediatr Infect Dis J* 2021;40(12):1115-1121. (In eng). DOI: 10.1097/INF.0000000000003284.
13. Nebbioso A, Ogundipe OF, Repetto EC, et al. When first line treatment of neonatal infection is not enough: blood culture and resistance patterns in neonates requiring second line antibiotic therapy in Bangui, Central African Republic. *BMC Pediatr* 2021;21(1):570. (In eng). DOI: 10.1186/s12887-021-02911-w.
14. Zamarano H, Musinguzi B, Kabajulizi I, et al. Bacteriological profile, antibiotic susceptibility and factors associated with neonatal Septicaemia at Kilembe mines hospital, Kasese District Western Uganda. *BMC Microbiol* 2021;21(1):303. (In eng). DOI: 10.1186/s12866-021-02367-z.

15. Paulson JN, Williams BL, Hehny C, et al. Infection with frequent viral coinfection contributes to postinfectious hydrocephalus in Ugandan infants. *Sci Transl Med* 2020;12(563) (In eng). DOI: 10.1126/scitranslmed.aba0565.
16. Isaacs AM, Morton SU, Movassagh M, et al. Immune activation during. *iScience* 2021;24(4):102351. (In eng). DOI: 10.1016/j.isci.2021.102351.
17. Morton SU, Hehny C, Burgoine K, et al. *Paenibacillus* Infection Causes Neonatal Sepsis and Subsequent Postinfectious Hydrocephalus in Ugandan Infants. . SSRN; 2022.
18. Drotar D, Olness K, Wiznitzer M, et al. Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. *Pediatrics* 1997;100(1):E5. (In eng). DOI: 10.1542/peds.100.1.e5.
19. Luna VA, King DS, Gullede J, Cannons AC, Amuso PT, Cattani J. Susceptibility of *Bacillus anthracis*, *Bacillus cereus*, *Bacillus mycoides*, *Bacillus pseudomycoides* and *Bacillus thuringiensis* to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. *J Antimicrob Chemother* 2007;60(3):555-67. (In eng). DOI: 10.1093/jac/dkm213.
20. Ouyang J, Pei Z, Lutwick L, et al. Case report: *Paenibacillus thiaminolyticus*: a new cause of human infection, inducing bacteremia in a patient on hemodialysis. *Ann Clin Lab Sci* 2008;38(4):393-400. (In eng).
21. Di Micco R, Schneider M, Nüesch R. Postoperative *Paenibacillus thiaminolyticus* Wound Infection, Switzerland. *Emerg Infect Dis* 2021;27(7):1984-1986. (In eng). DOI: 10.3201/eid2707.203348.
22. Hunt B, Rogers C, Blais RM, Adachi K, Sathyavagiswaran L. *Paenibacillus* Sepsis and Meningitis in a Premature Infant: A Case Report. *Am J Forensic Med Pathol* 2021;42(1):96-98. (In eng). DOI: 10.1097/PAF.0000000000000610.
23. Movassagh M, Bebell LM, Burgoine K, et al. Vaginal microbiome topic modeling of laboring Ugandan women with and without fever. *NPJ Biofilms Microbiomes* 2021;7(1):75. (In eng). DOI: 10.1038/s41522-021-00244-1.
24. Richter CA, Wright-Osment MK, Zajicek JL, Honeyfield DC, Tillitt DE. Quantitative polymerase chain reaction (PCR) assays for a bacterial thiaminase I gene and the thiaminase-producing bacterium *Paenibacillus thiaminolyticus*. *J Aquat Anim Health* 2009;21(4):229-38. (In eng). DOI: 10.1577/H07-054.1.
25. Dhawan S, Singh R, Kaur R, Kaur J. A  $\beta$ -mannanase from *Paenibacillus* sp.: Optimization of production and its possible prebiotic potential. *Biotechnol Appl Biochem* 2016;63(5):669-678. (In eng). DOI: 10.1002/bab.1419.
26. Dsouza M, Taylor MW, Turner SJ, Aislabie J. Genome-based comparative analyses of Antarctic and temperate species of *Paenibacillus*. *PLoS One* 2014;9(10):e108009. (In eng). DOI: 10.1371/journal.pone.0108009.
27. Chauhan NS, Joseph N, Shaligram S, et al. *Paenibacillus oleatilyticus* sp. nov., isolated from soil. *Arch Microbiol* 2022;204(8):516. (In eng). DOI: 10.1007/s00203-022-03116-0.
28. da Silva FKL, de Sa Alexandre AR, Casas AA, et al. Increased production of chitinase by a *Paenibacillus illinoisensis* isolated from Brazilian coastal soil when immobilized in alginate beads. *Folia Microbiol (Praha)* 2022 (In eng). DOI: 10.1007/s12223-022-00992-3.
29. Kumar S, Ujor VC. Complete Genome Sequence of *Paenibacillus polymyxa* DSM 365, a Soil Bacterium of Agricultural and Industrial Importance. *Microbiol Resour Announc* 2022;11(6):e0032922. (In eng). DOI: 10.1128/mra.00329-22.
30. Lee M, Ten LN, Baek SH, Im WT, Aslam Z, Lee ST. *Paenibacillus ginsengisoli* sp. nov., a novel bacterium isolated from soil of a ginseng field in Pocheon Province, South Korea. *Antonie Van Leeuwenhoek* 2007;91(2):127-35. (In eng). DOI: 10.1007/s10482-006-9102-x.

31. Dornelles LV, Procianoy RS, Roesch LFW, et al. Meconium microbiota predicts clinical early-onset neonatal sepsis in preterm neonates. *J Matern Fetal Neonatal Med* 2022;35(10):1935-1943. (In eng). DOI: 10.1080/14767058.2020.1774870.
32. Dang T, Loll B, Müller S, et al. Molecular basis of antibiotic self-resistance in a bee larvae pathogen. *Nat Commun* 2022;13(1):2349. (In eng). DOI: 10.1038/s41467-022-29829-w.
33. DeLeon SD, Welliver RC. *Paenibacillus alvei* Sepsis in a Neonate. *Pediatr Infect Dis J* 2016;35(3):358. (In eng). DOI: 10.1097/INF.0000000000001003.
34. Zhang E, Lu H, Liu Q, et al. *Paenibacillus assamensis* in Joint Fluid of Man with Suspected Tularemia, China. *Emerg Infect Dis* 2018;24(8):1589-1591. (In eng). DOI: 10.3201/eid2408.180260.
35. Wenzler E, Kamboj K, Balada-Llasat JM. Severe Sepsis Secondary to Persistent *Lysinibacillus sphaericus*, *Lysinibacillus fusiformis* and *Paenibacillus amylolyticus* Bacteremia. *Int J Infect Dis* 2015;35:93-5. (In eng). DOI: 10.1016/j.ijid.2015.04.016.
36. Isaacman DJ, Karasic RB, Reynolds EA, Kost SI. Effect of number of blood cultures and volume of blood on detection of bacteremia in children. *J Pediatr* 1996;128(2):190-5. (In eng). DOI: 10.1016/s0022-3476(96)70388-8.
37. Kellogg JA, Ferrentino FL, Goodstein MH, Liss J, Shapiro SL, Bankert DA. Frequency of low level bacteremia in infants from birth to two months of age. *Pediatr Infect Dis J* 1997;16(4):381-5. (In eng). DOI: 10.1097/00006454-199704000-00009.
38. Hehnly C, Zhang L, Paulson JN, et al. Complete Genome Sequences of the Human Pathogen *Paenibacillus thiaminolyticus* Mbale and Type Strain P. *thiaminolyticus* NRRL B-4156. *Microbiol Resour Announc* 2020;9(15) (In eng). DOI: 10.1128/MRA.00181-20.
39. Messbarger N, Neemann K. Role of Anaerobic Blood Cultures in Neonatal Bacteremia. *J Pediatric Infect Dis Soc* 2018;7(3):e65-e69. (In eng). DOI: 10.1093/jpids/pix088.
40. Birgisson H, Steingrimsson O, Gudnason T. *Kingella kingae* infections in paediatric patients: 5 cases of septic arthritis, osteomyelitis and bacteraemia. *Scand J Infect Dis* 1997;29(5):495-8. (In eng). DOI: 10.3109/00365549709011861.
41. Yagupsky P, Dagan R, Howard CW, Einhorn M, Kassis I, Simu A. High prevalence of *Kingella kingae* in joint fluid from children with septic arthritis revealed by the BACTEC blood culture system. *J Clin Microbiol* 1992;30(5):1278-81. (In eng). DOI: 10.1128/jcm.30.5.1278-1281.1992.
42. Che G, Liu F, Chang L, Lai S, Teng J, Yang Q. *Mycoplasma hominis* Meningitis Diagnosed by Metagenomic Next-Generation Sequencing in a Preterm Newborn: a Case Report and Literature Review. *Lab Med* 2022 (In eng). DOI: 10.1093/labmed/lmac078.
43. Qin L, Li YH, Cao XJ, et al. Clinical metagenomic sequencing for rapid diagnosis of neonatal meningitis caused by *Ureaplasma parvum*: A case report. *Medicine (Baltimore)* 2022;101(4):e28662. (In eng). DOI: 10.1097/MD.00000000000028662.
44. Decroix V, Goudjil S, Kongolo G, Mammeri H. '*Leptotrichia amnionii*', a newly reported cause of early onset neonatal meningitis. *J Med Microbiol* 2013;62(Pt 5):785-788. (In eng). DOI: 10.1099/jmm.0.051870-0.
45. Vitorino P, Varo R, Castillo P, et al. *Sneathia amnii* and Maternal Chorioamnionitis and Stillbirth, Mozambique. *Emerg Infect Dis* 2019;25(8):1614-1616. (In eng). DOI: 10.3201/eid2508.190526.
46. Kralik SF, Kukreja MK, Paldino MJ, Desai NK, Vallejo JG. Comparison of CSF and MRI Findings among Neonates and Infants with. *AJNR Am J Neuroradiol* 2019;40(8):1413-1417. (In eng). DOI: 10.3174/ajnr.A6134.
47. Xu M, Hu L, Huang H, et al. Etiology and Clinical Features of Full-Term Neonatal Bacterial Meningitis: A Multicenter Retrospective Cohort Study. *Front Pediatr* 2019;7:31. (In eng). DOI: 10.3389/fped.2019.00031.

48. Cromwell EA, Dube Q, Cole SR, et al. Validity of US norms for the Bayley Scales of Infant Development-III in Malawian children. *Eur J Paediatr Neurol* 2014;18(2):223-30. (In eng). DOI: 10.1016/j.ejpn.2013.11.011.
49. Pendergast LL, Schaefer BA, Murray-Kolb LE, et al. Assessing development across cultures: Invariance of the Bayley-III Scales Across Seven International MAL-ED sites. *Sch Psychol Q* 2018;33(4):604-614. (In eng). DOI: 10.1037/spq0000264.
50. Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics--systematic review and meta-analysis. *Arch Dis Child* 2013;98(2):146-54. (In eng). DOI: 10.1136/archdischild-2012-302033.
51. Thaver D, Ali SA, Zaidi AK. Antimicrobial resistance among neonatal pathogens in developing countries. *Pediatr Infect Dis J* 2009;28(1 Suppl):S19-21. (In eng). DOI: 10.1097/INF.0b013e3181958780.
52. Dharmapalan D, Shet A, Yewale V, Sharland M. High Reported Rates of Antimicrobial Resistance in Indian Neonatal and Pediatric Blood Stream Infections. *J Pediatric Infect Dis Soc* 2017;6(3):e62-e68. (In eng). DOI: 10.1093/jpids/piw092.
53. C H, A S, P S, et al. Type IV pili is a critical virulence factor in clinical isolates of *Paenibacillus thiaminolyticus*. *bioRxiv*; 2022.
54. Sáez-Nieto JA, Medina-Pascual MJ, Carrasco G, et al. spp. isolated from human and environmental samples in Spain: detection of 11 new species. *New Microbes New Infect* 2017;19:19-27. (In eng). DOI: 10.1016/j.nmni.2017.05.006.
55. Chu SM, Hsu JF, Lai MY, et al. Risk Factors of Initial Inappropriate Antibiotic Therapy and the Impacts on Outcomes of Neonates with Gram-Negative Bacteremia. *Antibiotics (Basel)* 2020;9(4) (In eng). DOI: 10.3390/antibiotics9040203.
56. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ. Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial bloodstream infections in a neonatal intensive care unit. *Infect Control Hosp Epidemiol* 2004;25(9):735-41. (In eng). DOI: 10.1086/502469.
57. Thaden JT, Ericson JE, Cross H, et al. Survival Benefit of Empirical Therapy for *Staphylococcus aureus* Bloodstream Infections in Infants. *Pediatr Infect Dis J* 2015 (In ENG). DOI: 10.1097/INF.0000000000000850.
58. Hsu JF, Chu SM, Wang HC, et al. Multidrug-Resistant Healthcare-Associated Infections in Neonates with Severe Respiratory Failure and the Impacts of Inappropriate Initial Antibiotic Therap. *Antibiotics (Basel)* 2021;10(4) (In eng). DOI: 10.3390/antibiotics10040459.
59. Kiwanuka J, Bazira J, Mwanga J, et al. The microbial spectrum of neonatal sepsis in Uganda: recovery of culturable bacteria in mother-infant pairs. *PLoS One* 2013;8(8):e72775. (In eng). DOI: 10.1371/journal.pone.0072775.
60. Popescu CR, Cavanagh MMM, Tembo B, et al. Neonatal sepsis in low-income countries: epidemiology, diagnosis and prevention. *Expert Rev Anti Infect Ther* 2020;18(5):443-452. (In eng). DOI: 10.1080/14787210.2020.1732818.
61. Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. *Paediatr Drugs* 2013;15(2):93-117. (In eng). DOI: 10.1007/s40272-013-0017-5.
62. Guardabassi L, Christensen H, Hasman H, Dalsgaard A. Members of the genera *Paenibacillus* and *Rhodococcus* harbor genes homologous to enterococcal glycopeptide resistance genes *vanA* and *vanB*. *Antimicrob Agents Chemother* 2004;48(12):4915-8. (In eng). DOI: 10.1128/AAC.48.12.4915-4918.2004.
63. Tsai AL, Hsieh YC, Chen CJ, et al. Investigation of a cluster of *Bacillus cereus* bacteremia in neonatal care units. *J Microbiol Immunol Infect* 2022;55(3):494-502. (In eng). DOI: 10.1016/j.jmii.2021.07.008.

64. Ap GR, Daga MK, Mawari G, et al. Effect of Supplementation of Vitamin C and Thiamine on the Outcome in Sepsis: South East Asian Region. *J Assoc Physicians India* 2022;70(3):11-12. (In eng).
65. Na W, Shen H, Li Y, Qu D. Hydrocortisone, ascorbic acid, and thiamine (HAT) for sepsis and septic shock: a meta-analysis with sequential trial analysis. *J Intensive Care* 2021;9(1):75. (In eng). DOI: 10.1186/s40560-021-00589-x.
66. Sevransky JE, Rothman RE, Hager DN, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. *JAMA* 2021;325(8):742-750. (In eng). DOI: 10.1001/jama.2020.24505.
67. Zhang L, Li S, Lu X, et al. Thiamine May Be Beneficial for Patients With Ventilator-Associated Pneumonia in the Intensive Care Unit: A Retrospective Study Based on the MIMIC-IV Database. *Front Pharmacol* 2022;13:898566. (In eng). DOI: 10.3389/fphar.2022.898566.
68. Li T, Bai J, Du Y, et al. Thiamine pretreatment improves endotoxemia-related liver injury and cholestatic complications by regulating galactose metabolism and inhibiting macrophage activation. *Int Immunopharmacol* 2022;108:108892. (In eng). DOI: 10.1016/j.intimp.2022.108892.
69. Raj KM, Baranwal AK, Attri SV, et al. Thiamine Status in Children with Septic Shock from a Developing Country: A Prospective Case-Control Study. *J Trop Pediatr* 2021;67(1) (In eng). DOI: 10.1093/tropej/fmaa107.
70. Donnino MW, Andersen LW, Chase M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. *Crit Care Med* 2016;44(2):360-7. (In eng). DOI: 10.1097/CCM.0000000000001572.
71. Measelle JR, Baldwin DA, Gallant J, et al. Thiamine supplementation holds neurocognitive benefits for breastfed infants during the first year of life. *Ann N Y Acad Sci* 2021;1498(1):116-132. (In eng). DOI: 10.1111/nyas.14610.
72. Sambon M, Wins P, Bettendorff L. Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. *Int J Mol Sci* 2021;22(11) (In eng). DOI: 10.3390/ijms22115418.